Re: Darolutamide plus Androgen-deprivation Therapy and Docetaxel in Metastatic Hormone-sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase III ARASENS Trial

Salil S. Ghamande, Zachary Klaassen, Christopher J.D. Wallis

Research output: Contribution to journalComment/debatepeer-review

Original languageEnglish (US)
Pages (from-to)350-351
Number of pages2
JournalEuropean urology
Volume84
Issue number3
DOIs
StatePublished - Sep 2023

ASJC Scopus subject areas

  • Urology

Cite this